生产企业：Ryvu Therapeutics SA
SEL-120 (RVU120, SEL120; romaciclib) is a clinical-stage, first-in-class selective dual inhibitor of CDK8 and CDK19 kinases, key components of the mediator complex responsible for regulating gene transcription. By targeting these kinases it disrupts transcriptional programs that support cancer cell survival and maintain the undifferentiated state.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
